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Background: Chemotherapy with praziquantel (PZQ) has been the cornerstone of schistosomiasis control over the
last two decades. Being the only available drug for the treatment of over 200 million people worldwide, continuous
monitoring of PZQ efficacy under the pressure of widespread use is therefore advocated.
Methods: The efficacy of taking two doses of oral PZQ for the treatment of Schistosoma haematobium was
examined among school children in Nigeria. Urine specimens were collected from 350 school children and
examined using the filtration technique. Blood was collected for packed cell volume (PCV) estimation, and the
weight and height of each child were estimated. S. haematobium egg positive pupils were treated with two oral
doses of PZQ at 40 mg/kg with a four-week interval in between. Drug efficacy was determined based on the egg
reduction rate (ERR).
Results: Among 350 school children, 245 (70.0%) – of which 132 were males and 113 were females, with an age
range of 4 to 15 years – were diagnosed with S. haematobium. All the 245 infected children received a single oral
dose of 40 mg/kg PZQ twice with a four-week interval in between and were followed up for 12 weeks. At four,
eight and twelve weeks post treatment, the ERR was 57.1%, 77.6% and 100%, respectively. The ERR was significantly
higher among the children with a light infection compared to those with a heavy infection. One hundred and
twenty-one children were egg negative at four weeks post treatment, among which 1 (6.3) and 120 (52.4%) had
heavy and light infections, respectively. Following the second round of treatment, the cure rate at eight weeks and
twelve weeks was 85.3% and 100%, respectively.
Conclusion: This study demonstrated the efficacy of taking two doses of oral PZQ for the treatment of urinary
schistosomiasis among school children in Nigeria.
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Background
Schistosomiasis is responsible for significant health
problems and is a socioeconomic burden in most of
Sub-Saharan Africa and some other tropical countries
[1,2]. It is endemic in 74 countries, with the bulk of the
cases globally (90%) residing in Sub-Saharan Africa [3,4].
The significant health problems associated with schisto-
somiasis include impaired cognitive potential among pri-
mary school-age children, hepatosplenomegaly, anaemia,
bladder cancer and stunted growth [5]. Also genital
schistosomiasis, which manifests at reproductive age if
schistosomiasis is not treated, is attributed as a risk fac-
tor for HIV transmission [6].
Currently the antischistosomal drug of choice for the
treatment of schistosomiasis is praziquantel (PZQ). It is
the mainstay of the current strategy against schistosom-
iasis morbidity control and is highly effective against the
five schistosome species that infect humans [7]. Prazi-
quantel is a pyrazinoquinoline derivative and its safety
and efficacy have ensured its widespread usage. It is rec-
ommended that school-aged children and high-risk
groups of adults in communities with a prevalence of
10% to 50% use it once every two years. In communities
where the prevalence is above 50%, both children and
adults are required to be treated once a year [8]. Prazi-
quantel has been used widely successfully in many na-
tional control programmes. However, there is evidence
of clinical relevant resistance developing [9].
The extensive use of PZQ and the problem of reduced
therapeutic efficacy is on the increase globally, and this
has led to the growing concern regarding the use of a
single drug for the treatment of a disease affecting more
than 200 million people [10]. Already countries such as
Egypt [11], Zimbabwe [5] and Cameroon [12] have re-
ported low cure rates of PZQ. There is therefore a need
for constant and continuous monitoring of PZQ under
the pressure of widespread use. A critical aspect in the
assessment of PZQ efficacy is the drug’s activities during
the different parasite development stages. Experimental
laboratory studies have shown that activities of PZQ are
stage dependent with the drug acting primarily against
the adult worm stages, whereas immature schistosomes
(two to four weeks old) are less susceptible [13]. All
these observations point towards the need for the devel-
opment of new potent drugs or combinations of drugs
that will be effective against all stages of the parasite.
While this is still being awaited, there is a need for con-
stant monitoring of PZQ efficacy in endemic areas.Although the prevalence and incidence of S. haemato-
bium has been largely reported in Nigeria [14-16], the effi-
cacy of PZQ among school children has not been well
documented in some highly endemic areas as the drugs
are distributed on a large scale without monitoring or
follow-up. Therefore, this study was conducted to evaluate
the efficacy of taking two doses of oral PZQ for treatment,
given as two single doses of 40 mg/kg with a four-week
interval in between. Repeated doses of PZQ given two to
eight weeks after the initial dose in endemic areas of
Africa have been shown to have incremental benefits
when compared to single doses [17,18].Methods
Study site and subjects
This study was carried out among primary and second-
ary school children in Akala and Imala Odo (Oyan) in
the Abeokuta North Local Government area of Ogun
State between July 2011 and March 2012. The commu-
nities were located close to the bank of the Oyan Reser-
voir which has been shown to be endemic [19]. The
communities had no health centre at the time of the
study. Although there is a schistosomiasis co-ordinating
unit at the local government council, its activity is ham-
pered by the irregular supply of PZQ. The study enrolled
350 primary and secondary school children, aged four to
fifteen years. The age of each child was determined based
on school records, and the weight and height were mea-
sured using a ruler and a weighing scale, respectively.Screening of urine
Universal bottles labelled with the corresponding iden-
tification number were given to each participating
child. Each participants was asked to produce the urine
specimen between 10:00 and 14:00, and submit it on
the same day. The samples were transported to the
laboratory for microscopic examination of S. haemato-
bium eggs using the urine filtration method. Briefly,
10 ml of well-mixed urine was aspirated and slowly
forced through a filter membrane. The filter was
removed and placed on a slide, covered with a cover
slip and examined under a light microscope [20]. The
number of eggs on the entire filter was counted and
recorded as the number of eggs per 10 ml urine
(EP10ml). From the total slides, 10% were randomly
selected and re-examined by an independent micro-
scopist for quality control. A Combur-Test (Roche
Diagnostics GmbH, Mannheim, Germany) reagent strip
was used to detect the presence of blood in the urine.
For those participants whose slides came out negative,
urine samples were collected on two successive days to
confirm that they were truly negative.
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For packed cell volume (PCV), microhematocrit tubes
filled with blood were centrifuged in a microhematocrit
rotor for five minutes at 10,000 g. Packed cell volumes
values ≤ 31% were considered as anaemia, which was fur-
ther classified as mild (21–30%), moderate (15–20%) or
severe (≤15%).
Treatment and follow-up
All children who provided urine specimens in the pre-
treatment survey were included in the analysis of infec-
tion patterns at baseline, but only the children positive
for S. haematobium eggs were treated with two single
oral doses (40 mg/kg) of PZQ, given with a four-week
interval in between. The drug was administered with a
glass of water following the confirmation that the child
ate at home or ate food that was provided by the investi-
gating team. Urine samples were taken on the fourth,
eighth and twelfth week to monitor the cure and egg re-
duction rates.
Ethical consent
Approval for the study was obtained from the Ethical
Committee of the Ogun State Ministry of Health in
Abeokuta. Before the onset of the study, a meeting was
held with the community heads and the parents of the
school children where formal, oral informed consent
was obtained from the parents and the children directly
before the sample collection.
Data analysis
Data was entered into a Microsoft Excel spreadsheet and
exported to SPSS (version 16) (SPSS Inc., Chicago, IL,
USA) for analysis. The proportion of children infected
with S. haematobium was expressed as prevalence. The
chi-square test and one-way ANOVA were used to test
for differences in the prevalence of infections and geo-
metric mean egg counts, respectively. P-values < 0.05
were considered statistically significant. The intensity re-
duction rate was calculated as [1 − (GM egg counts per
10 mL of urine after treatment/GM egg counts perTable 1 Prevalence and mean egg count/10 ml urine, by sex a




Male 186 132 (70.9)
Female 164 113 (68.9)
p-value 0.73
Age (years)
4–9 203 143 (70.4)
10–15 147 102 (69.4)
p-value 0.9010 mL before treatment)] × 100 [21]. The cure rate was
calculated as [the number of children excreting no S.
haematobium eggs/the number of children with con-
firmed infections before treatment] x 100.
Results
Of the 350 children (age range four to fifteen years; 186
male, 164 female) enrolled into the study, 245 (70.0%) –
132 males and 113 females – were positive for S. haema-
tobium, determined using the urine filtration technique.
The age group of four to nine years had the highest
prevalence (70.4%), but the difference was not statisti-
cally significant. There was no significant difference in
the intensity of infection according to sex or age in the
study. The proportion of males (5.9%) that had a heavy
infection was greater than females (3.1%), but the differ-
ence was not statistically significant. The age group of
four to nine years had the highest proportion (5.4%) of
those with a heavy infection but this difference was also
not statistically significant (see Table 1).
Figure 1 shows the operational results and PZQ treat-
ment outcomes over a 12-week period. Two hundred
and forty-five children were treated twice (with a four-
week interval in between) over a 12-week period with
follow-up. All 245 infected children received a single
oral dose of 40 mg/kg of PZQ and another single dose
of 40 mg/kg four weeks later under the supervision of
their teachers and members of the study team. The over-
all ERR at four weeks, eight weeks and 12 weeks post
treatment was 57.1%, 77.6% and 100%, respectively. The
efficacy of PZQ in this study at 12 weeks post treatment
is therefore considered satisfactory [21]. The cure rate at
four weeks, eight weeks and twelve weeks was 49.4%,
85.5% and 100%, respectively.
Before treatment, 6.5% (geometric mean egg 116.4
egg/gm) of the children were heavily infected (>50 eggs/
10 ml), while 93% (geometric mean egg 8.2egg/gm) were
lightly infected. At four weeks post treatment (before
the second dose of PZQ), only 1 (6.3%) child was para-
site free among those who were heavily infected. There







11 (5.9) 121 (65.1) 10.98
5 (3.1) 108 (65.9) 7.37
0.30 0.91
11 (5.4) 132 (65.0) 7.93
05 (3.4) 97 (66.0) 6.73
0.67 0.72
Figure 1 Study compliance for the efficacy of praziquantel to treat S. haematobium among school children in Abeokuta, Nigeria.
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(p = 0.0001). At eight weeks and twelve weeks (after the
second dose of PZQ), 7 (43.8%; ERR 96.4%) and 16
(100%; ERR 100%) were parasite free, respectively,
among those who were heavily infected. For those who
were lightly infected, the ERR at four weeks, eight weeks
and twelve weeks was 58.9%, 73.1% and 100%, respect-
ively. The drug showed an overall cure rate of 49.4%,
85.3% and 100% at four weeks, eight weeks and twelve
weeks, respectively (see Table 2).
Generally none of the pupils examined in the study popu-
lation, either infected or non-infected with schistosomiasis,
were anaemic. A significant difference was observed
when the level of infection was compared with the
mean PCV in the study population (p = 0.017). The
mean weight and height of the pupils were also com-
pared with respect to the infection level but the differ-
ence was not significant. A significant difference was
observed when the presence of urine in the blood was
compared with the different levels of infection (see
Table 3). At the baseline cross-sectional survey, 228 of
the 245 S. haematobium infected children had visible
blood in their urine with a prevalence of 93.0%. At four
weeks post treatment, only 2 (1.2%) children had blooddetected, while none of the children had blood in their
urine by the eighth and twelfth week.
Discussion
Praziquantel remains the drug of choice for the treat-
ment of schistosomiasis in spite of cases of low cure
rates that have been reported in some areas [22,23]. As
there have been reports of therapeutic failures [24,25],
constant surveillance of PZQ efficacy is imperative while
we wait for the discovery and development of more po-
tent drugs. In this study, the performance of PZQ was
considered satisfactory since the ERRs during the eighth
and twelfth weeks were 77.6% and 100%, respectively
[21]. Our results also demonstrated that there is a sig-
nificant difference between the cure rates and infection
intensities which is in agreement with previous studies
where cure rates were shown to be consistently higher
in individuals with light infections before treatment than
in those with moderate or heavy infections [17,26]. In
some studies, factors such as high pre-treatment egg in-
tensities, poor drug absorption and a high rate of PZQ
catabolism, rather than parasite resistance, have been at-
tributed to the reduced PZQ cure rate in endemic areas
[5]. The criteria of cure based on the absence of eggs
Table 2 Cure rates, geometric mean egg counts and intensity reduction rates over 12 weeks in 245 school children infected with Schistosoma haematobium
after one treatment with praziquantel in Ogun State, Nigeria































< 50 229 (93.5) 8.2 120 52.4 3.37 58.9 199 87.0 2.2 73.1 229 100.0 0.0 100.0
≥ 50 16 (6.5) 116.4 1.00 6.3 13.4 88.5 7.0 43.8 4.2 96.4 16 100.00 0.0 100.0



















Table 3 Comparison between PCV, weight, height and blood in urine in relation to S. haematobium intensity of











PCV (geo mean) ± SD 34.21 ± 2.7 33.86 ± 2.6 35.7 ± 2.5 0.017
Weight (mean) ± SD 23.57 ± 7.5 23.42 ± 7.3 25.50 ± 5.2 0.97
Height (geo mean) ± SD 116.73 ± 18.7 116.24 ± 20.5 114.94 ± 22.7 0.94
Blood in urine (%) 17 (16.2) 212 (92.6) 16 (100) < 0.000
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96% depending on the intensity of the infection. At four
weeks post treatment before the administration of the sec-
ond single dose of 40 mg/kg, only 49.3% of the study popu-
lation treated were parasite free. At eight weeks post
treatment, after the second dose of PZQ, 15% of the treated
population were still egg positive. Most of the previous
studies have reported a higher efficacy of PZQ when ad-
ministered as two or three treatments spaced at certain
time intervals [23,27]. It is assumed that patients in high
transmission areas would harbour a high number of imma-
ture schistosomes that are less susceptible to PZQ [28,29].
These immature schistosomes have a high chance of sur-
viving a single PZQ treatment. Another explanation is the
suggestion that PZQ kill worms slowly or that dead worms
still have the ability to release eggs [12]. The dead eggs may
be present for months in the urine of treated patients in-
fected with S. haematobium and will falsely reduce the egg
reduction and cure rate results. Although we did not deter-
mine the viability of the excreted eggs, some studies have
reported that dead eggs may be present for several months
in the urine of S. haematobium infected individuals [12].
The high prevalence of S. haematobium reported in this
study reflects the current transmission situation and on-
going control challenges in this area. Many epidemio-
logical studies emanating from this region over the years
have consistently revealed a high prevalence of urinary
schistosomiasis [14,30,15]. Some of these reports show
that the community members are aware that their con-
stant continuous contact with endemic water from the
river is responsible for their high infection rates, but be-
cause there is no alternative water source they have no
choice but to continue to depend on the contaminated
water for their daily domestic activities [31]. An alternative
source of water and a well-laid-out control strategy by
policy makers coupled with regular PZQ treatment are
therefore needed in other to put an end to the menace of
urinary schistosomiasis in this region.
No significant difference was observed in the preva-
lence between males (70.9%) and females (68.9%), as well
as between the different ages in this study. This pattern of
infection may be an indication of the equal exposure ofboth genders and the ages examined in the study due to
significant water contact activities. The observed preva-
lence of microhematuria (70%) in the overall study popula-
tion was similar to what was previously reported in this
study area [19]. No significant difference was observed re-
garding microhematuria between ages and sexes, and this
may be explained by the fact that microhematuria is a
characteristic symptom of urinary schistosomiasis in en-
demic communities and its prevalence has been shown
to correlate positively with urinary schistosomiasis in-
fection. This prevalence decreased rapidly during the
fourth and eighth week following PZQ treatment. This
finding is in agreement with previous studies that sug-
gest that urine reagent strips could potentially estimate
the intensity of S. haematobium infection in endemic
areas [31,20]. The current WHO guidelines for preventive
chemotherapy recognize hematuria prevalence, in addition
to egg count-based criteria, as an effective means to iden-
tify communities with high, moderate or low risk for
schistosomiasis [32].
An unusual result observed in our study was that none
of the students infected with either a light or heavy S. hae-
matobium infection were anaemic. We observed that the
mean PCV of pupils with heavy infection intensity was
significantly higher than pupils with a light infection or
those who were not infected. Many previous studies have
demonstrated a high prevalence of anaemia among school
children living in S. haematobium endemic areas [33,16].
While anaemia is well associated with schistosomiasis
based on the pathogenesis of blood loss that results from
S. haematobium infection, the blood loss could also be
compensated with foods such as fish and green leafy vege-
tables which are abundantly available and consumed in
these local communities. The unexpected observation in
this study could raise important questions that need fur-
ther research. In a similar manner, the S. haematobium in-
fection status has no influence on the weight and height
of the students in this endemic area.
Conclusion
This study demonstrated the efficacy of PZQ against S.
haematobium in Nigeria. In view of the fact that the use
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widely-used drug, constant monitoring of drug resist-
ance becomes imperative. It would also be beneficial to
investigate the effects of repeated therapeutic doses of
PZQ at different time intervals since repeated doses have
been reported to produce a higher efficacy in compari-
son to single treatment in endemic areas. There is need
to explore other alternative treatment regimens such the
PZQ and artemisinin (ACT) derivatives combination as
ACT derivatives have been shown to be active against
immature schistosome worms [34]. There is need for a
more co-ordinated effort by the government through the
provision of alternative water sources that are cercariae
free, through continuous and constant mass drug ad-
ministration and through integrated vector control in
order to bring an end to the ravaging scourge of this dis-
ease in this area.
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